[Inhibition of the free, biologically active testosterone level by Turisteron in patients with prostate cancer].
Apart from their antigonadotropic effect oestrogens also directly inhibit the androgen secretion of the testicles. Thus, on the 20th day of treatment the LH-level after 12 g diethylstilbestrol diphosphate (DSDP) decreases only to approximately 50% of the initial value, while the whole testosterone (T), however, is reduced to less than 5%. The sexual hormone binding globulin is significantly more increased (p less than 0.001) by the estrogen treatment than after orchidectomy only. Therefore, the free, biologically active T-level in the plasma consists of more than one third of the level after exclusive orchidectomy. The treatment with the depot estrogen Turisteron is clarly superior to the usual treatment Oestrasid implants. Both with and without orchidectomy the free testosterone level is significantly lower than after Oestrasid implants plus orchidectomy. Therefore, this therapy can successfully be used in the treatment of the carcinoma of the prostate also without orchidectomy.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003692:Delayed-Action Preparations; D004054:Diethylstilbestrol / Q000031:analogs & derivatives / Q000627:therapeutic use; D004997:Ethinyl Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013739:Testosterone / Q000097:blood*
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D012738:Sex Hormone-Binding Globulin; C025723:ethinyl estradiol sulfonate; D013739:Testosterone; D004997:Ethinyl Estradiol; D004054:Diethylstilbestrol; D007986:Luteinizing Hormone; C004955:fosfestrol
Auffallend starke Hemmung des freien, biologisch aktiven Testosteronspiegels durch Behandlung mit Turisteron bei Patienten mit Prostatakarzinom.